Dashboard
Manage Tickers

SVRA Savara Inc

Nasdaq savarapharma.com


$ 4.16 $ -0.15 (-3.49 %)    

Friday, 31-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.15 $ 0.00 (0 %)
DIA $ 475.97 $ 0.00 (0 %)
SPY $ 684.54 $ 0.00 (0 %)
TLT $ 90.01 $ 0.00 (0 %)
GLD $ 368.48 $ 0.00 (0 %)
$ 4.15
$ 4.29
$ 4.08 x 5
$ 4.47 x 34
-- - --
$ 1.89 - $ 4.51
1,298,791
na
717.27M
$ 0.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-13-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-savara-announces-130m-public-offering-including-238m-shares-and-71m-pre-funded-warrants-priced-at-420-per-share
Reported Earlier, Savara Announces $130M P...
10/30/2025 08:16:07

Savara intends to use the proceeds from the offering for general corporate purposes, which include the funding of clinical deve...

savara-announces-common-stock-offering-terms-not-disclosed
Savara Announces Common Stock Offering; Te...
10/29/2025 20:08:10

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today...

savara-announces-75m-financing-agreement-with-rtw-investments
Savara Announces $75M Financing Agreement ...
10/29/2025 20:03:19

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, anno...

savaras-partner-trilliumbio-to-present-encore-data-on-development-of-dried-blood-spot-test-to-aid-in-diagnosis-of-apap-at-chest-2025
Savara's Partner, TrilliumBiO, To Present ...
10/02/2025 20:09:07

savara-presents-new-data-from-phase-3-impala-2-showing-molgramostim-beneficial-in-apap-patients-regardless-of-disease-severity
Savara Presents New Data From Phase 3 IMPA...
09/29/2025 07:22:12

– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by ...

guggenheim-maintains-buy-on-savara-raises-price-target-to-11
Guggenheim Maintains Buy on Savara, Raises...
09/09/2025 13:00:26

Guggenheim analyst Vamil Divan maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $8 to $11.

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-8
Oppenheimer Maintains Outperform on Savara...
09/08/2025 12:22:40

Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $6 t...

hc-wainwright--co-maintains-buy-on-savara-raises-price-target-to-8
HC Wainwright & Co. Maintains Buy on Savar...
09/03/2025 14:36:20

HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $5...

savara-reveals-that-the-results-from-the-phase-3-impala-2-clinical-trial-will-be-published-online-in-nejm--in-the-largest-clinical-trial-conducted-in-autoimmune-pap-molgramostim-inhalation-solution-reduced-surfactant-burden-and-improved-pulmonary-gas-transfer-respiratory-health-related-quality-of-life-and-patient-functionality
Savara Reveals That The Results From The P...
08/20/2025 21:19:25

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, annou...

savara-announces-it-will-present-new-data-from-phase-3-impala-2-trial-of-molgramostim-inhalation-solution-in-patients-with-autoimmune-pulmonary-alveolar-proteinosis-at-european-respiratory-society-congress-2025
Savara Announces It Will Present New Data ...
08/18/2025 12:10:09

Savara's Partner, TrilliumBiO, to Present Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPA...

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-6
Oppenheimer Maintains Outperform on Savara...
08/15/2025 14:32:05

Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $5 ...

hc-wainwright--co-upgrades-savara-to-buy-raises-price-target-to-5
HC Wainwright & Co. Upgrades Savara to Buy...
08/15/2025 13:09:00

HC Wainwright & Co. analyst Andrew S. Fein upgrades Savara (NASDAQ:SVRA) from Neutral to Buy and raises the price target...

savara-q2-eps-014-misses-012-estimate
Savara Q2 EPS $(0.14) Misses $(0.12) Estimate
08/13/2025 12:15:25

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 1...

this-starbucks-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday
This Starbucks Analyst Is No Longer Bullis...
05/29/2025 12:42:02

hc-wainwright--co-downgrades-savara-to-neutral-lowers-price-target-to-2
HC Wainwright & Co. Downgrades Savara to N...
05/29/2025 11:05:47

HC Wainwright & Co. analyst Andrew Fein downgrades Savara (NASDAQ:SVRA) from Buy to Neutral and lowers the price target ...

hc-wainwright--co-downgrades-savara-to-neutral-lowers-price-target-to-2
HC Wainwright & Co. Downgrades Savara to N...
05/29/2025 11:05:47

HC Wainwright & Co. analyst Andrew Fein downgrades Savara (NASDAQ:SVRA) from Buy to Neutral and lowers the price target ...

evercore-isi-group-maintains-in-line-on-savara-lowers-price-target-to-2
Evercore ISI Group Maintains In-Line on Sa...
05/28/2025 16:06:02

Evercore ISI Group analyst Liisa Bayko maintains Savara (NASDAQ:SVRA) with a In-Line and lowers the price target from $3 to $2.

guggenheim-maintains-buy-on-savara-lowers-price-target-to-8
Guggenheim Maintains Buy on Savara, Lowers...
05/28/2025 14:04:29

Guggenheim analyst Vamil Divan maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $9 to $8.

wells-fargo-maintains-overweight-on-savara-lowers-price-target-to-7
Wells Fargo Maintains Overweight on Savara...
05/28/2025 13:07:47

Wells Fargo analyst Tiago Fauth maintains Savara (NASDAQ:SVRA) with a Overweight and lowers the price target from $8 to $7.

why-is-rare-lung-disease-focused-savara-stock-trading-lower-on-tuesday
Why Is Rare Lung Disease-Focused Savara St...
05/27/2025 19:40:10

Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION